Jubilant Pharmova Limited
Add to watch list to get report alerts
BSE Code:
530019
NSE Code:
JUBLPHARMA
Business Profile
Business Profile
Jubilant Organosys is an integrated pharmaceutical industry player with a wide range of products and services for global life sciences companies. The company has custom research and manufacturing services (CRAMS) and drug discovery services in India. It was originally incorporated as Vam Organic Chemicals in the year 1978. Jubilant is based at Noida, Uttar Pradesh and it has its branches at West Bengal, Tamil Nadu, Karnataka, Gujarat, Andhra Pradesh and Maharashtra.
Jubilant Organosys is a manufacturer in defined product segments, including select APIs (e.g., Carbamazepine and Citalopram), Pyridine and its derivatives, Solid polyvinyl acetate, Vinyl Pyridine Latex and Organic Intermediates (e.g., Ethyl Acetate and Acetic Anhydride). Apart from 4 manufacturing facilities in India, the company also has a US FDA approved manufacturing facility for dosage forms in Maryland, USA. Jubilant Organosys has three subsidiary companies in India - Jubilant Biosys for bio/chemo informatics databases & drug discovery services, Jubilant Chemsys for medicinal chemistry services and Jubilant Clinsys forclinical research. PSI N.V. and PSI Supply N.V., in which Jubilant Organosys holds 80% equity, are the Belgium based pharmaceuticals companies providing regulatory affairs services and supply of dosage forms to European generic companies. Jubilant Pharmaceuticals, Inc., in USA and Clinsys, Inc.,a clinical research organization (CRO) operating out of the USA, are also subsidiaries of the company.
Financials
Jubilant Organosys swung to a loss for the quarter ended in December 2008. During the quarter, the company reported loss of Rs 211.60 million compared with a profit of Rs 851 million in the same quarter last year. Net sales for the quarter rose 19.23% to Rs 5896.10 million, while total income for the quarter rose 15.70% to Rs 5,910.2 million, when compared with the prior year period. It reported loss of Rs 1.44 a share during the quarter compared with earnings of Rs 5.92 a share in prior year period.
Recent Developments
11-JUN-09
Jubilant Biosys, subsidiary of the company, has inked a discovery and development collaboration with US based pharma company, Endo Pharmaceuticals.
05-MAY-09
The company`s subsidiary, Jubilant Biosys has inked a research collaboration agreement with AstraZeneca.
04-MAY-09
The company announced today that its subsidiary in the United States, Draximage LLC received US Food and Drug Administration (FDA) approval for the company`s Abbreviated New Drug Application (ANDA) for Draximage`s generic Sestamibi.
09-APR-09
The company announced that its subsidiaries Jubilant Biosys (Bangalore based) and Jubilant Chemsys (Noida based) entered into three way drug discovery partnership with Orion, a leading pharmaceutical company of Finland.
13-MAR-09
Fitch has assigned a National Long Term rating of `A+(ind)` to the company with Stable outlook.
12-MAR-09
The company`s arm Draximage has inked an agreement with France based Guerbet for the distribution of its nuclear medicine products in Europe.
02-MAR-09
The company`s Canadian arm, Draxis received approval for the generic Sestamibi injection from Health Canada.
06-FEB-09
The company has bought back part of the foreign currency convertible bonds (FCCBs) due 2011, amounting to USD 11.1 million at a discount, in compliance with RBI regulations and the same have been cancelled on Feb. 05, 2009.
21-JAN-09
The company announced that its Bangalore based subsidiary Jubilant Biosys has developed a next generation screening solution, Legend NGSS.
13-JAN-09
The company announced that its Bangalore-based subsidiary Jubilant Biosys has entered into a drug discovery partnership with BioLeap, LLC, USA.
Future Plans
The company is planning to set up a new R&D centre for development of dosage forms. The facility, spread over an area of 20,000 sq. ft, will develop new processes and products going off patent in years to come and also the new drug delivery systems for products still under patent.